# Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

> **NCT05611853** · PHASE1,PHASE2 · TERMINATED · sponsor: **BioNova Pharmaceuticals (Shanghai) LTD.** · enrollment: 9 (actual)

## Conditions studied

- B-cell Lymphoma
- Non Hodgkin Lymphoma
- Diffuse Large B Cell Lymphoma
- Follicular Lymphoma
- Mantle Cell Lymphoma

## Interventions

- **DRUG:** BN301

## Key facts

- **NCT ID:** NCT05611853
- **Lead sponsor:** BioNova Pharmaceuticals (Shanghai) LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-11-25
- **Primary completion:** 2023-12-25
- **Final completion:** 2023-12-25
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Due to company decision
- **Last updated:** 2024-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05611853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05611853, "Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT05611853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*